Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients

NCT ID: NCT04714203

Last Updated: 2021-01-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 38 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-06-01
• Study Completion Date: 2019-08-31

Brief Summary

Cancer is one of the leading causes of death in the world after cardiovascular disease (8.7 million deaths in 2015 for 17.5 million cases) 1. Despite a great deal of progress in disease detection and treatment, the incidence of cancer is steadily increasing (+ 33% in 2015) and particularly in certain locations (pancreas, lungs, brain and stomach), including risk factors are not always identified.

Advanced stage cancer (= metastatic) is most often incurable with the exception of germ cell tumors. Palliative care is then most often offered. Palliative care favors the patient's quality of life as a whole (medical, physical, psychological and social).

The symptoms most often reported by patients are: pain, fatigue, decreased appetite, nausea, and are directly related to phenomena such as cachexia, loss of autonomy and deterioration of psychological state, resulting in decreased overall survival. Chemotherapies and targeted therapies (immunotherapy, hormonal therapy, participation in a clinical trial) can provide a benefit in quality of life and survival only in the early phase (little benefit in the terminal phase).

Other prognostic factors can impact the quality of life and overall survival in these situations: sarcopenia and disorders of nutritional status (obesity, undernutrition).

The study of sarcopenia by CT scan of patients in a palliative situation is still too scarce. Sarcopenia is an often underestimated event and is associated with older age, co-morbidities, increased infectious complications, and early mortality.

The study of the prevalence of sarcopenia by CT scan would confirm its prognostic impact in a palliative situation.

Conditions

Metastatic Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

cohort

Sarcopenia assessment

sarcopenia assessment

Intervention Type: OTHER

evaluation of sarcopenia status

Interventions

sarcopenia assessment

evaluation of sarcopenia status

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• age> 18 years old,
• patient with solid cancer diagnosed with metastatic disease,
• having had a biological assessment and a CT scan in the month preceding the medical consultation,
• and whose prognosis is considered palliative

Exclusion Criteria

• age <18 years old,
• adults under guardianship measure,
• pregnancy or breastfeeding in progress,
• malignant hemopathies,
• metastatic germ cell tumors,
• non-metastatic disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Weprom

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Katell LE DU, MD

Role: PRINCIPAL_INVESTIGATOR

Clinique Victor Hugo/Centre Jean Bernard

Locations

Clinique Victor Hugo / Centre Jean Bernard

Le Mans, , France

Countries

France

Other Identifiers

WP-2019-04

Identifier Type: -

Identifier Source: org_study_id